Trial Profile
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms JUSTICE
- 08 Mar 2023 Planned initiation date changed from 1 Jan 2023 to 1 Apr 2023.
- 15 Dec 2022 Planned initiation date changed from 1 Nov 2022 to 1 Jan 2023.
- 26 Sep 2022 Status changed from not yet recruiting to recruiting.